Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of “Buy” by Brokerages

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been given an average rating of “Buy” by the nine brokerages that are currently covering the stock, MarketBeat reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $9.71.

A number of brokerages recently commented on ACRS. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target (down previously from $20.00) on shares of Aclaris Therapeutics in a report on Wednesday, May 14th. Wedbush initiated coverage on Aclaris Therapeutics in a research note on Wednesday, May 28th. They issued an “outperform” rating and a $8.00 price objective for the company. Scotiabank cut their target price on Aclaris Therapeutics from $15.00 to $9.00 and set a “sector outperform” rating on the stock in a research report on Friday, May 9th. Finally, Cantor Fitzgerald started coverage on Aclaris Therapeutics in a report on Tuesday, March 18th. They set an “overweight” rating on the stock.

Aclaris Therapeutics Stock Performance

Shares of ACRS stock opened at $1.57 on Thursday. The stock has a fifty day simple moving average of $1.30 and a two-hundred day simple moving average of $2.06. The firm has a market capitalization of $170.00 million, a PE ratio of -3.02 and a beta of 0.41. Aclaris Therapeutics has a 52-week low of $1.05 and a 52-week high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, sell-side analysts forecast that Aclaris Therapeutics will post -0.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. ExodusPoint Capital Management LP bought a new stake in shares of Aclaris Therapeutics during the fourth quarter worth $26,000. Invesco Ltd. bought a new position in Aclaris Therapeutics in the 4th quarter worth about $28,000. Graham Capital Management L.P. purchased a new position in shares of Aclaris Therapeutics during the fourth quarter worth approximately $35,000. Commonwealth Equity Services LLC bought a new stake in shares of Aclaris Therapeutics during the fourth quarter valued at approximately $36,000. Finally, Alpine Global Management LLC purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $38,000. 98.34% of the stock is owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.